At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Mar 4, 2026 at 19:00 ET
PTC Therapeutics CEO Matthew Klein sold $170,600 of stock in an open-market transaction, while Director Stephanie Okey exercised options and sold 1,167 shares for $81,700. The CEO also received a non-cash award of 12,500 shares. Total open-market sales in the cluster amount to $252,300, representing a minor 0.005% of the company's $5.2B market cap.
- CEO Matthew Klein sold 2,662 shares for $170,581 in an open-market transaction.
- CEO also received a non-cash grant of 12,500 shares (no economic cost).
- Director Stephanie Okey exercised options and sold 1,167 shares for $81,690.
- All transactions are within normal insider activity patterns; no large-scale selling or coordinated exits.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access